Novo Nordisk As operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novo Nordisk As with three other
pharmaceutical manufacturers in Europe:
Lonza Group AG
sales of 5.92 billion Swiss Francs [US$6.29 billion]
of which 70%
(16.15 billion Euros [US$18.25 billion]
of which 42%
was Life Science), and
based in UNITED KINGDOM
(£19.06 billion [US$24.07 billion]
of which 100%
During the year ended December of 2019, sales at
Novo Nordisk As were 122.02 billion Danish Kroner (US$18.51 billion).
increase of 9.1%
versus 2018, when the company's sales were 111.83 billion Danish Kroner.
Sales of Diabetes and Obesity saw an increase
9.5% in 2019, from
93.90 billion Danish Kroner to 102.84 billion Danish Kroner.